No, you won't find a list of "12 benefits of CBD" here. A French seller is not allowed to write that CBD treats, relieves, prevents or cures anything: that's not a surface-level precaution, it's the law. What you can have instead is an honest look at what research has actually established, at what level of evidence, and what it leaves open.
The only thing resembling an effect of CBD recognized by a health authority is a prescription medicine, Epidyolex, reserved for severe childhood epilepsies. Everything else — relaxation, sleep, stress — is a matter of individual, unevenly documented feeling, never a promise.
The word "benefits" appears in this article for one reason only: to explain to you why a CBD shop is not allowed to use it.
Key points — The only medical use of CBD recognized by a health authority is Epidyolex, a prescription medicine for severe childhood epilepsies, unrelated to the flowers and resins sold in shops. Consumers report a subjective, variable relaxation, with no high. The WHO concluded in 2018 that CBD has a good safety profile and no potential for abuse; EFSA ruled in 2022 that safety data remained insufficient, particularly on the liver. Drowsiness, digestive issues and drug interactions via liver enzymes are documented. No health claim is authorized on an over-the-counter product.
What consumers actually describe
What comes up most often in user feedback is a feeling of relaxation, a moment of pause, closer to an evening ritual than a pronounced effect. No high, no altered perception: CBD does not get you high, whatever the percentage shown on the label.
Three honest clarifications are needed:
- It varies from person to person. Some describe a clear release, others don't feel anything definite. Neither case is abnormal.
- Expectation shapes the feeling. Context — sitting down, putting your phone away, breathing — is part of the experience, as much as the molecule itself.
- It's not measurable like a medicine. A flower or resin has no leaflet, no indication, no validated dose. You're exploring a product, not following a protocol.
The only recognized medical use: a medicine, not a shop flower
Epidyolex (cannabidiol) is today the only cannabinoid to have obtained a marketing authorization in Europe, in 2019, for rare and severe forms of childhood epilepsy: Dravet syndrome, Lennox-Gastaut syndrome, tuberous sclerosis complex. This authorization rests on randomized clinical trials, strict medical follow-up, and quantities far higher than what a shop flower or resin contains.
This is a point often distorted by marketing: "CBD has a marketing authorization" becomes "CBD treats." In reality, a marketing authorization validates one specific medicine, at one specific quantity, for one specific population, under medical supervision. It says nothing about a product bought online for its taste or its evening ritual. CBD is also combined with THC in Sativex, authorized in France for spasticity in multiple sclerosis — another medicine, again outside the scope of shop products.
Understanding levels of evidence before believing a catchy headline
A good part of the confusion comes from mixing results that don't carry the same weight:
- Preclinical (cells, animals). Most of the leads cited in "benefits" articles — action on inflammation, oxidative stress, certain cancer cells — come from this level. They guide research; they prove nothing in humans.
- Small human trials. A few dozen participants, often under controlled lab conditions, sometimes single-blind. Useful for exploring a lead, insufficient to draw a general conclusion.
- Robust trials. Randomized, placebo-controlled, with a sufficient number of participants and an appropriate duration. This is the level that allowed Epidyolex's authorization. Very few other uses of CBD have reached this level of evidence.
A "benefit" that exists only at the preclinical level has no place in a commercial promise. That's exactly what French law reminds sellers of.
What the WHO, EFSA and ANSM say
The WHO: a good safety profile, not a therapeutic green light
The World Health Organization's Expert Committee on Drug Dependence published a critical report on CBD in 2018. Its conclusion: CBD has a good safety profile and shows no effects indicating a potential for abuse or dependence in humans. This is a risk assessment, not a recognition of efficacy: the WHO did not rule on benefits.
EFSA: data still insufficient
In 2022, the European Food Safety Authority published a statement on the safety of CBD as a "novel food." Its conclusion is clear: public data are insufficient to establish the safety of regular consumption, particularly effects on the liver, the digestive system, the nervous system and reproduction, the latter observed in animal studies. This statement put on hold all the authorization applications filed in Europe.
ANSM: vigilance on interactions
The French National Agency for the Safety of Medicines and Health Products (ANSM) grants no recognition of benefits for over-the-counter CBD products. Its role mainly concerns safety: it has, for example, warned about interactions between CBD and medicines, pointing out that mixing them is "never harmless," whatever form the product takes.
The documented adverse effects
Clinical trials conducted on Epidyolex, at pharmaceutical quantities far higher than those in a shop product, have shown regular adverse effects: drowsiness, fatigue, diarrhoea, appetite changes. A systematic review published in 2020 in Neuropsychopharmacology confirms this profile and notes, particularly at high quantities and combined with certain anti-epileptic drugs such as valproate, a rise in liver enzymes.
CBD is metabolized by the liver via cytochrome enzymes, notably CYP3A4 and CYP2C19. These are the same enzymes that break down a long list of common medicines: anticoagulants, certain anti-epileptics, certain antidepressants, immunosuppressants. By slowing them down, CBD can change the blood concentration of these treatments. That's why anyone on medication should talk to a doctor or pharmacist before taking CBD, whatever form the product takes.
Why be wary of "12 proven benefits" lists
These lists almost always rely on the same trick: citing a cell study next to a human study, without specifying the level of evidence, and turning a researcher's "might" into a marketing "relieves." A few pointers for reading them critically:
- Check whether the study was conducted in humans, not just on cells or in animals.
- Look at the number of participants. A handful of volunteers doesn't allow generalization.
- Look for whether the trial is placebo-controlled. Without a comparison, there's no way to tell a real effect from an expectation effect.
- Be wary of absolute words: "proven," "validated," "scientifically demonstrated" attached to a use that in reality has only preclinical data.
What we can tell you, and what we can't
WorldWeed sells CBD flowers and CBD resins, not a treatment. We can tell you about an endocannabinoid system studied in the lab, about a feeling of relaxation reported by consumers, about a precise French legal framework. We can't tell you that Strawberry or Tyson will help you sleep, feel less stressed or suffer less. If you're looking for a specific therapeutic effect, the right step is to talk to a doctor, not to read a product page. CBD is not recommended for minors, pregnant or breastfeeding women, and medical advice is needed if you're on medication — see also the details on side effects and safety profile.
Sources
- World Health Organization, Expert Committee on Drug Dependence (ECDD), Cannabidiol (CBD) Critical Review Report, June 2018.
- EFSA, « Statement on safety of cannabidiol as a novel food: data gaps and uncertainties », EFSA Journal, June 2022 — efsa.europa.eu.
- ANSM, « Mélanger CBD et médicaments, ce n'est jamais anodin », news release, March 2025 — ansm.sante.fr.
- Chesney E., Oliver D., Green A. et al., « Adverse effects of cannabidiol: a systematic review and meta-analysis of randomized clinical trials », Neuropsychopharmacology, 2020.
- European Medicines Agency (EMA), marketing authorization for Epidyolex (cannabidiol), 2019.
- Devinsky O. et al., « Cannabidiol in Dravet syndrome », New England Journal of Medicine, 2017.
